Amicus Therapeutics, Inc. (FOLD) Earnings History
Annual and quarterly earnings data from 2005 to 2025
Loading earnings history...
FOLD EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
FOLD Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 87.3% | 5.4% | -4.3% |
| 2024 | 90.0% | 4.7% | -10.6% |
| 2023 | 90.7% | -19.3% | -38.0% |
| 2022 | 88.3% | -64.4% | -71.9% |
| 2021 | 88.7% | -67.6% | -82.0% |
Download Data
Export FOLD earnings history in CSV or JSON format
Free sign-in required to download data
Amicus Therapeutics, Inc. (FOLD) Earnings Overview
As of May 8, 2026, Amicus Therapeutics, Inc. (FOLD) reported trailing twelve-month net income of -$27M, reflecting +51.2% year-over-year growth. The company earned $-0.09 per diluted share over the past four quarters, with a net profit margin of -4.3%.
Looking at the long-term picture, FOLD's historical earnings data spans multiple years. The company achieved its highest annual net income of -$7M in fiscal 2009.
Amicus Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RARE (-$609M net income, -85.4% margin), SRPT ($65M net income, -32.5% margin), BMRN ($269M net income, 10.8% margin), FOLD has outperformed on profitability metrics. Compare FOLD vs RARE →
FOLD Earnings vs Peers
Earnings metrics vs comparable public companies
FOLD Historical Earnings Data (2005–2025)
21 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$27M | +51.7% | $34M | $-0.09 | -4.3% | 5.4% |
| 2024 | -$56M | +63.0% | $25M | $-0.18 | -10.6% | 4.7% |
| 2023 | -$152M | +35.9% | -$77M | $-0.51 | -38.0% | -19.3% |
| 2022 | -$237M | +5.5% | -$212M | $-0.82 | -71.9% | -64.4% |
| 2021 | -$250M | +9.5% | -$206M | $-0.92 | -82.0% | -67.6% |
| 2020 | -$277M | +22.3% | -$247M | $-1.07 | -106.1% | -94.7% |
| 2019 | -$356M | -2.1% | -$304M | $-1.48 | -195.6% | -166.8% |
| 2018 | -$349M | -22.9% | -$329M | $-1.88 | -382.5% | -360.3% |
| 2017 | -$284M | -42.0% | -$442M | $-1.85 | -769.0% | -1196.8% |
| 2016 | -$200M | -51.4% | -$182M | $-1.49 | -4034.7% | -3668.6% |
See FOLD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FOLD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare FOLD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonFOLD — Frequently Asked Questions
Quick answers to the most common questions about buying FOLD stock.
Is FOLD growing earnings?
FOLD EPS is $-0.09, with earnings growth accelerating to +51.2%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-27M.
What are FOLD's profit margins?
Amicus Therapeutics, Inc. net margin is -4.3%, with operating margin at +5.4%. Below-average margins reflect competitive or cost pressures.
How consistent are FOLD's earnings?
FOLD earnings data spans 2005-2025. The accelerating earnings trend is +51.2% YoY. Historical data enables comparison across business cycles.